NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Prothena Corporation plc (PRTA) Stock Analysis

Prothena Corporation plc (PRTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PRTA

$9.82

+$0.22 (+2.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRTA with… →

PRTA Key Statistics

As of Sep 4, 2026
Trading
Open
$9.50
Previous Close
$9.60
Day's Range
9.48–9.87
52-Week Range
7.73–11.80
Volume
383.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.33
Valuation
Market Cap
$504.13M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.82
Financials (FY)
Revenue (FY)
$9.68M−92.83%
Net Income (FY)
−$244.09M
Profit marginThe share of revenue left as profit after all costs and taxes.
−80.68%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.34M
1-Year Return
+19.61%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
513.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRTA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.83%
2025−31.05%
2024−61.89%
2023−39.68%
2022+21.96%
2021+311.32%
2020−24.13%
2019+53.69%
2018−72.53%
2017−23.79%
2016 (partial year)−13.21%

As of September 4, 2026.

PRTA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$9.68M−$244.09M−2520.6%
2024$135.16M−$122.31M−90.5%
2023$91.37M−$147.03M−160.9%
2022$53.91M−$116.95M−217.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.68M—−$184.56M−$244.09M−2520.6%
2024$135.16M—−$154.56M−$122.31M−90.5%
2023$91.37M—−$191.04M−$147.03M−160.9%
2022$53.91M—−$131.56M−$116.95M−217.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRTA Valuation vs Biotechnology Median

Median of 656 stocks
MetricPRTABiotechnology medianvs median
P/S ratio9.2415.2639% below
Profit margin−80.68%0.00%80.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Prothena Corporation plc (PRTA) is capitalised at $504.13M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 67 employees.

The most recent close on file for PRTA is $9.82, dated September 4, 2026. That is +$0.22 (+2.29%) against the previous close. Over the past 52 weeks the price has ranged from $7.73 to $11.80. The latest close sits 27.04% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $9.68M. Against the prior fiscal year total of $135.16M, that is a change of −92.83%. The same year closed with a net loss of $244.09M. Profit margin runs at −80.68%. That is 80.7 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.82.

Across the 4 fiscal years on file, revenue moves from $53.91M in 2022 to $9.68M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 9.24. On price-to-sales that is 39.43% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +19.61%. Across 10 years the annualized return works out at −15.38%. Beta against the wider market is reported at −0.33. Annualized volatility over the trailing 10 years is 75.47%.

Growth & Income

No dividend is on file for PRTA.

2026 is still running; the price is +2.83% year to date. The strongest complete calendar year on file is 2021 at +311.32%; the weakest is 2018 at −72.53%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Prothena Corporation plc (PRTA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Prothena Corporation plc PRTA $504.13M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Prothena Corporation plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Prothena Corporation plc

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Visit website →